The influence of class II HLA type on the lymphoproliferative response of normal donors to a bcr-abl fusion peptide.

Published

Journal Article

Chronic myelogenous leukemia (CML) is characterized by a t(9;22) chromosomal translocation resulting in the expression of a novel bcr-abl fusion protein. The region spanning the fusion point is novel to the immune system and hence represents a potential leukemia-specific antigen. The ability of a 21-mer b3a2 fusion peptide to induce an in vitro lymphoproliferative response in a panel of 54 normal donors has been tested. This gave a mean stimulation index of 2.73 (95% CI 2.42-3.05) and 50/54 (93%) of donors gave responses that were greater than those with bcr or abl control peptides. The mean stimulation index relative to that of the control peptides was 1.80 (95% CI 1.63-1.97; p < 0.001). Responses were optimal at concentrations ranging from 0.3-150 micrograms/mL and in most cases peaked at 9 days. There was no clear relationship between level of responsiveness to the b3a2 fusion peptide and the presence of any single HLA-A, -B, -DR, or -DQ allele. HIA-DRB1*0404 was the only allele that was not associated with responsiveness. It is therefore likely that the b3a2 fusion peptide can be presented to T cells during a primary immune response in the context of several different class II HLA allelic products, albeit at low efficiency. The implications for specific active immunotherapy of CML patients are discussed.

Full Text

Duke Authors

Cited Authors

  • MacIntyre, AR; Christmas, SE; Clark, RE

Published Date

  • September 1996

Published In

Volume / Issue

  • 24 / 11

Start / End Page

  • 1307 - 1311

PubMed ID

  • 8862441

Pubmed Central ID

  • 8862441

International Standard Serial Number (ISSN)

  • 0301-472X

Language

  • eng

Conference Location

  • Netherlands